T cells are pivotal mediators of the adaptive immune response, with cytotoxic CD8+ T lymphocytes recognising peptides displayed by MHC class I molecules. This antigen presentation process involves the ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main ...

PANoptosis, an emerging concept in immunology, refers to a form of programmed cell death that integrates various signaling ...

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or ...

The evolution of immunotherapy, featuring CAR-T cells and senolytics, highlights potential in cancer treatment and challenges ...

Nanovaccines show promise in breast cancer therapy, enhancing immune activation and targeting cold tumors, particularly in ...

Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...